Welcom to Sichuan Hengkang Science and Technology Development Co.,Ltd.
Other Heterocyclic Compounds
Advanced Drug Intermediates
Intermediates of Ibrutinib
Intermediates of Ozanimod
Intermediates of Upadacitinib
Intermediates of Zanubrutinib
Protected Amino acids
The most difficult target may be conquered! Adagrassib, a new drug for lung cancer, is on the market!
by admin on 22-04-11
On February 15, 2022, the U.S. Food and Drug Administration (FDA) accepted the adagrassib new drug application (NDA) for the treatment of patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutation who had received at least one systemic treatment before. Under the prescription drug u...
Porton ：The revenue of CDMO of gene cell therapy was 13.87 million yuan, up 897% year on year
by admin on 22-04-02
On March 25,Porton Shares (300363) released its annual report: In 2021, the company achieved an operating income of 3.105 billion yuan, up 50% year on year, and the revenue scale reached a record high. The net profit attributable to shareholders of listed companies after excluding non-recurring g...
Apeloa Pharmaceutical signed an agreement with MPP to produce Pfizer’s oral COVID-19 treatment to 95 low-and middle-income countries
by admin on 22-03-22
On March 19th, Apeloa Pharmaceutical Co., LTD. (stock code: 000739) announced, The Company signs the License Agreement with MPP (the “Drug Patent Pool Organization”), MPP grants the Company non-exclusive, non-transferable, non-subcontracted, commercial and related rights for nematvir ...
Sanofi and SOBI: The recombinant factor VIII therapy reaches a phase III endpoint for severe hemophilia A
by admin on 22-03-21
On March 9,2022, Sanofi and its partner Swedish Orphan Biovitrum AB (“SOBI”), an international biopharmaceutical company focused on rare diseases, released positive results for their ongoing phase III trial, XTEND-1, for hemophilia A candidate Efanesoctocog alfa (BIVV001).This is a no...
Summary of new drug approval and expanded indications for the FDA in January 2022
by admin on 22-03-01
1.Quviviq Quviviq (generic name: daridorexant) is a drug for insomnia and is a dual orexin receptor antagonist (OXR).The therapeutic mechanism is achieved by competitively combining OXR1 and OXR2, inhibiting orexin signaling function and thereby blocking the arousal pathway to inhibit the hypera...
New TOP10 forecast for a bestseller in 2022
by admin on 22-02-23
Recently, the Nature subsidiary magazine Nature Review Drug Discovery and the biomedical industry media Evaluate Vantage have both published articles on the analysis and prediction of the global drug sales of Top10 in 2022. Two analysis article gives the same forecast, in the list, there are two ...
With the multiple sclerosis drug sales rankings released in 2021, the Roche Ocrevus firmly ranked first
by admin on 22-02-14
With the release of companies’ 2021 financial results, the sales list of multiple sclerosis (MS) drugs in 2021 is also released, as listed in the table below.It is worth mentioning that the MS sector has now seen six blockbuster products with sales of more than $1 billion. Roche’s ...
2022 Spring Festival Holiday notice
by admin on 22-01-19
Dear Customer: The Spring Festival of 2022 is coming. Combined with the equipment maintenance situation of the production workshop of our company, the company has decided that the 2022 Spring Festival holiday will be notified as follows: I. Production Department from January 19, 2022 to Februar...
The AI auxiliary design drug pipeline has entered the IND-Enabling Studies stage within 8 months
by admin on 22-01-19
On January 17,2022, focusing on the use of artificial intelligence driven drug development announced, use its independent research and development of integrated AI new drug discovery platform Molecule Pro, in 8 months to design, verified 69 new small molecules and obtained for a class B G protein...
The latest study: complete vaccination can not prevent Oikjon, strengthening needle efficiency is only 37%
by admin on 22-01-10
Before many people get the third shot, a new warning from the Moderna CEO comes here.Recently, he said publicly that as the drug effectiveness will decline over time, people may need a fourth dose in the fall to boost protection. Stephane Bancel said people receiving booster needles last fall ma...
Merck partners with Thermo Fisher to manufacture molnupiravir in Canada
by admin on 22-01-07
Thermo Fisher will dedicate its manufacturing facility in Ontario, Canada to make Merck’s molnupiravir and distribute the drug in Canada and the UK Merck headquarters in Darmstadt, Germany. (Credit: Merck KGaA.) Merck has reached an agreement with healthcare technology company Thermo Fisher Sci...
Outlook 2022: Industry forecasts 19 blockbuster new drugs to be approved
by admin on 22-01-04
As of December 31,78 innovative drugs have been approved this year, including the 21 innovative drugs predicted at the beginning of the year.With 2022 about to open, what innovative drugs are expected to be available?The industry expects 19 blockbuster new drugs to be approved, with cancer drugs ...
Page 1 / 2
Hit enter to search or ESC to close